Table 1.

MCRs common to primary and secondary glioblastoma

Cytogenetic bandLocus (Mb)Minimal common regionMCR recurrence
Position (Mb)Size (Mb)Peak valueNo. transcriptsGain loss (%)Amp/del (%)Known novelVerified by quantitative PCR
Gain and amplification
1p31.1-1p22.376.09-86.9276.09-86.9210.820.464713.55.4Novel
1q32.1-1q32.1198.16-198.57198.16-198.570.411.00416.25.4KnownNAV1
1q32.1-1q32.2200.47-203.98200.47-203.983.511.865913.52.7KnownGAC1
1q44-1 q44240.54-241.85240.54-241.851.311.901113.52.7Novel
3p26.3-3p24.30.42-21.4510.95-11.570.621.18510.85.4Novel
3p26.3-3p24.30.42-21.4512.91-13.830.921.18510.85.4NovelHDAC11 and WNT7A
4p12-4p1247.43-47.9047.43-47.900.470.9645.42.7Novel
4q11-4q13.152.80-62.5953.45-56.072.632.43118.15.4KnownPDGFRα
5q31.2-5q31.2138.98-139.89138.98-139.890.910.491110.82.7Novel
7p11.2-7p11.254.41-56.4354.41-55.260.854.39475.937.8KnownEGFR (PGBM only)
7q22.1-7q32.1101.70-126.60115.79-121.295.502.701877.818.9KnownMET, CAV1 (SGBM only)
9p21.2-9p13.226.83-37.6232.44-32.530.090.93310.85.4Known
9q34.3-9q34.3135.62-136.57135.62-136.570.950.421813.52.7NovelMRPL41; CACNA1B
12q13.2-12q13.354.51-55.2754.88-55.270.390.691710.88.1KnownRAP1B
12q13.3-12q14.155.31-57.5556.21-56.280.073.64332.424.3KnownCDK4
12q14.3-12q1565.02-66.8865.02-66.881.852.6168.15.4NovelDYRK2?
12q15-12q1566.92-69.8067.00-67.950.954.281024.321.6KnownMDM2
15q23-15q24.168.12-72.2571.38-71.790.410.67616.28.1Novel
15q26.3-15q26.399.66-100.2099.66-100.200.540.60510.82.7Novel
19p13.12-19q13.1115.77-40.2019.75-24.134.380.773356.88.1NovelGPATC1, SLC7A10 (in locus)
Loss and deletion
1p36.33-1p36.221.55-9.357.83-9.121.28−0.681424.313.5Known
1p31.1-1p22.277.73-89.0378.12-87.529.40−0.484113.55.4Novel
1q32.2-1q42.12203.98-223.12214.89-220.655.76−0.633118.910.8Known
1q43-1q44236.39-245.42244.52-244.850.32−1.191410.810.8NovelOR2M7 and OR2T4
2q37.1-2q37.1233.25-234.03233.25-234.030.78−0.601013.55.4NovelTNRC15 and INPP5D
4p13-4p1244.01-48.7247.77-48.720.95−0.55108.15.4Novel
5p15.33-5p15.310.23-9.680.91-3.652.74−0.511924.38.1Known
6p25.3-6p22.30.29-17.710.29-0.350.06−1.33221.68.1NovelDUSP22
6q16 2-6q2199.42-107.22105.28-105.830.55−0.65540.724.1Known
8p22-8p1213.30-30.0416.01-17.131.12−0.78613.58.1Known
9p24.3-9p21.10.20-30.5421.06-21.990.93−2.302255.646.3Knownp16
10q22.1-10q24.3174.43-102.7584.73-89.594.86−1.382885.246.3KnownPTEN
10q22.1-10q24.3174.43-102.7590.68-91.050.37−2.13581.544.4Known
10q22.1-10q24.3174.43-102.7592.49-102.7310.24−0.6410481.544.4Known
10q24.32-10q25.2104.38-112.03104.38-112.037.65−0.643679.640.7KnownMXI1 and others
10q25.2-10q26.3112.04-135.24120.43-121.380.95−1.27983.348.1KnownGPR10 and GRK5
10q25.2-10q26.3112.04-135.24123.71-129.786.08−1.274885.248.1KnownGPR10 and GRK5
10q25.2-10q26.3112.04-135.24133.87-135.021.16−1.271785.248.1Known
11p15.4-11p15.45.71-5.825.73-5.790.07−3.11629.616.7Known
11q11-11q1155.07-55.2955.09-55.190.09−2.43329.613.0KnownOR4C11 and OR4S2
11q11-11q12.355.32-63.0957.34-61.914.57−0.4711418.95.4KnownLOC390183
11q14.1-11q23.182.21-112.6285.82-89.563.73−0.582024.38.1KnownGPR83
11q14.1-11q23.182.21-112.6293.55-94.440.89−0.931014.810.8KnownGPR84
11q14.1-11q23.182.21-112.6295.20-102.066.87−0.621927.08.1Known
12p13.2-12p13.111.31-14.5412.37-12.830.46−0.62710.85.4NovelLOH1CR12
12q21.1-12q21.3173.73-80.1573.73-75.651.92−0.651016.78.1Novel
12q22-12q24.2394.19-118.9997.43-97.490.07−0.65213.58.1Known
12q22-12q24.2394.19-118.99105.88-112.296.40−0.518116.28.1Novel
12q24.32-12q24.32127.71-131.09130.94-131.070.11−0.51310.85.4Novel
13q12.11-13q13.319.14-35.6419.66-20.640.99−0.601132.418.9Known
14q11.2-14q11.219.40-19.5519.40-19.510.11−0.68333.337.8Known
15q13.3-15q15.330.71-41.8740.43-41.020.59−0.68822.216.2NovelZFP106, TTBK2, FLJ23375
15q25.2-15q26.380.20-97.4980.20-88.177.97−0.577324.38.1Novel
17q21.2-17q21.235.77-36.9736.59-36.660.07−2.45418.513.5Known
18p11.32-18p11.220.20-10.666.95-10.663.71−0.701627.018.9Known
19q13.2-19q13.4347.16-63.7647.78-48.550.77−0.971924.310.8Known
19q13.2-19q13.4347.16-63.7653.06-54.831.76−0.598424.310.8KnownAURKC (and others)
  • Abbreviations: PGBM, primary glioblastoma; SGBM, secondary glioblastoma.